Beam Therapeutics (BEAM) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $24.73, +4.57% vs the prior close of $23.65.
- Volume 1.76M shares, 1.0x its 50-day average.
- New SEC filings: 144 (Oct 15, 2026).
- No new insider buys or sales reported since the prior session.
BEAM jumps 4.6% to $24.73. Closed at $24.73, +4.57% vs the prior close of $23.65. Day range $23.20–$24.98, opened at $23.51.
BEAM daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — BEAM jumps 4.6% to $24.73
- Closed at $24.73, +4.57% vs the prior close of $23.65. Day range $23.20–$24.98, opened at $23.51.
- Volume was 1.76M shares, 1.0x its 50-day average of 1.83M.
- Price is -6.1% vs its 50-day average ($26.34) and -12.8% vs its 200-day average ($28.37).
- 52-week range $20.23–$38.26; today's close sits at 25% of that range, 35.4% below the 52-week high.
Oct 14, 2026 — BEAM slides 3.2% to $23.65, 3 down days in a row
- Closed at $23.65, -3.19% vs the prior close of $24.43. Day range $23.28–$24.26, opened at $24.13.
- Volume was 1.66M shares, 0.9x its 50-day average of 1.84M.
- Price is -10.4% vs its 50-day average ($26.38) and -16.7% vs its 200-day average ($28.39).
- 52-week range $20.23–$38.26; today's close sits at 19% of that range, 38.2% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — BEAM dips 2.8% to $24.43
- Closed at $24.43, -2.79% vs the prior close of $25.13. Day range $24.08–$24.93, opened at $24.88.
- Volume was 1.67M shares, 0.9x its 50-day average of 1.83M.
- Price is -7.7% vs its 50-day average ($26.48) and -14.0% vs its 200-day average ($28.41).
- 52-week range $20.23–$38.26; today's close sits at 23% of that range, 36.1% below the 52-week high.
Oct 12, 2026 — BEAM dips 2.2% to $25.13
- Closed at $25.13, -2.22% vs the prior close of $25.70. Day range $24.93–$26.09, opened at $25.63.
- Volume was 1.41M shares, 0.8x its 50-day average of 1.82M.
- Price is -5.2% vs its 50-day average ($26.51) and -11.6% vs its 200-day average ($28.43).
- 52-week range $20.23–$38.26; today's close sits at 27% of that range, 34.3% below the 52-week high.
Oct 9, 2026 — BEAM jumps 4.5% to $25.70
- Closed at $25.70, +4.47% vs the prior close of $24.60. Day range $24.55–$26.23, opened at $24.72.
- Volume was 1.80M shares, 1.0x its 50-day average of 1.81M.
- Price is -3.1% vs its 50-day average ($26.52) and -9.6% vs its 200-day average ($28.44).
- 52-week range $20.23–$38.26; today's close sits at 30% of that range, 32.8% below the 52-week high.
Oct 8, 2026 — BEAM dips 0.7% to $24.60, 3 down days in a row
- Closed at $24.60, -0.69% vs the prior close of $24.77. Day range $23.91–$24.69, opened at $24.26.
- Volume was 2.43M shares, 1.4x its 50-day average of 1.80M.
- Price is -7.3% vs its 50-day average ($26.53) and -13.5% vs its 200-day average ($28.45).
- 52-week range $20.23–$38.26; today's close sits at 24% of that range, 35.7% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — BEAM dips 1.8% to $24.77
- Closed at $24.77, -1.82% vs the prior close of $25.23. Day range $24.45–$25.37, opened at $24.64.
- Volume was 2.34M shares, 1.3x its 50-day average of 1.80M.
- Price is -6.7% vs its 50-day average ($26.56) and -13.0% vs its 200-day average ($28.46).
- 52-week range $20.23–$38.26; today's close sits at 25% of that range, 35.3% below the 52-week high.
Oct 6, 2026 — BEAM dips 1.7% to $25.23
- Closed at $25.23, -1.71% vs the prior close of $25.67. Day range $24.86–$26.94, opened at $26.80.
- Volume was 2.52M shares, 1.4x its 50-day average of 1.78M.
- Price is -5.1% vs its 50-day average ($26.59) and -11.4% vs its 200-day average ($28.47).
- 52-week range $20.23–$38.26; today's close sits at 28% of that range, 34.1% below the 52-week high.
Oct 5, 2026 — BEAM jumps 4.8% to $25.67
- Closed at $25.67, +4.78% vs the prior close of $24.50. Day range $23.83–$26.04, opened at $24.48.
- Volume was 2.00M shares, 1.1x its 50-day average of 1.78M.
- Price is -3.4% vs its 50-day average ($26.59) and -9.8% vs its 200-day average ($28.47).
- 52-week range $20.23–$38.26; today's close sits at 30% of that range, 32.9% below the 52-week high.
Oct 2, 2026 — BEAM rises 0.5% to $24.50
- Closed at $24.50, +0.45% vs the prior close of $24.39. Day range $24.21–$25.48, opened at $25.00.
- Volume was 1.50M shares, 0.8x its 50-day average of 1.81M.
- Price is -7.8% vs its 50-day average ($26.58) and -14.0% vs its 200-day average ($28.48).
- 52-week range $20.23–$38.26; today's close sits at 24% of that range, 36.0% below the 52-week high.
BEAM latest news & SEC filings
Every SEC filing by or about BEAM in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 2, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Cavanagh Bethany J sold 187 shares at $24.41 (≈$4.56K) on Oct 1, 2026; now holds 50,984
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 25, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Ciaramella Giuseppe gifted 123,407 shares on Sep 24, 2026; now holds 130,504
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 4, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $490.00K (prior year $8.47M) (-94.2% vs Jun 30, 2025)
- Net income: -$122.68M (prior year -$102.14M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$1.18 (prior year -$1.00) (loss widened vs Jun 30, 2025)
Aug 4, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 29, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Simon Amy sold 16,667 shares at $25.74 (≈$429.01K) on Jul 27, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 27, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jul 2, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Simon Amy sold 373 shares at $34.73 (≈$12.95K) on Jun 30, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Things to know before you trade BEAM
- Last results release: Aug 4, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 24, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Nov 3, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.12% (largest 6.0%).
- Liquidity: about 1.83M shares (≈$45.28M) trade per day on average.
- 52-week position: $24.73 vs a range of $20.23–$38.26 (25% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Amy Simon sold 16,667 shares on Jul 27, 2026.
- Latest filings: 10-Q Aug 4, 2026; 8-K Aug 4, 2026; 8-K Jun 8, 2026.
- Share count: 103.29M shares outstanding (Jul 28, 2026), +2.1% vs a year earlier.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
BEAM market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 23.51 | 24.98 | 23.20 | 24.73 | 1.76M |
| Oct 14, 2026 | 24.13 | 24.26 | 23.28 | 23.65 | 1.66M |
| Oct 13, 2026 | 24.88 | 24.93 | 24.08 | 24.43 | 1.67M |
| Oct 12, 2026 | 25.63 | 26.09 | 24.93 | 25.13 | 1.41M |
| Oct 9, 2026 | 24.72 | 26.23 | 24.55 | 25.70 | 1.80M |
| Oct 8, 2026 | 24.26 | 24.69 | 23.91 | 24.60 | 2.43M |
| Oct 7, 2026 | 24.64 | 25.37 | 24.45 | 24.77 | 2.34M |
| Oct 6, 2026 | 26.80 | 26.94 | 24.86 | 25.23 | 2.52M |
| Oct 5, 2026 | 24.48 | 26.04 | 23.83 | 25.67 | 2.00M |
| Oct 2, 2026 | 25.00 | 25.48 | 24.21 | 24.50 | 1.50M |
| Oct 1, 2026 | 24.24 | 24.98 | 23.95 | 24.39 | 1.69M |
| Sep 30, 2026 | 24.79 | 25.20 | 24.41 | 24.45 | 1.56M |
| Sep 29, 2026 | 23.88 | 24.76 | 23.88 | 24.52 | 1.64M |
| Sep 28, 2026 | 24.02 | 24.66 | 23.44 | 24.23 | 1.27M |
| Sep 25, 2026 | 24.97 | 24.97 | 23.75 | 24.27 | 1.22M |
| Sep 24, 2026 | 23.88 | 24.81 | 23.16 | 24.66 | 2.28M |
| Sep 23, 2026 | 25.75 | 26.24 | 24.22 | 24.37 | 1.90M |
| Sep 22, 2026 | 25.62 | 26.50 | 25.07 | 25.93 | 1.99M |
| Sep 21, 2026 | 25.45 | 25.66 | 24.83 | 25.26 | 1.70M |
| Sep 18, 2026 | 24.92 | 25.18 | 24.26 | 24.95 | 2.29M |
About Beam Therapeutics
Beam Therapeutics (BEAM) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in CAMBRIDGE, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1745999.
BEAM board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Graham K Cooper | Director | Jun 5, 2026 |
| John M. Evans | CEO | Jul 1, 2026 |
| Mark Fishman | Director | Jun 5, 2026 |
| Chirfi Guindo | Director | Jun 5, 2026 |
| John Maraganore | Director | Jun 5, 2026 |
| Christi Shaw | Director | Jun 5, 2026 |
| Kathleen E Walsh | Director | Jun 5, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Christine Bellon | Chief Legal Officer | Apr 6, 2026 |
| Bethany J Cavanagh | SVP, Finance and Treasurer | Apr 6, 2026 |
| Giuseppe Ciaramella | President | Sep 25, 2026 |
| Sravan Kumar Emany | Chief Financial Officer | Apr 2, 2026 |
| John M. Evans | CEO | Jul 1, 2026 |
| Amy Simon | Chief Medical Officer | Jul 29, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 27, 2026 | Amy Simon | Sale | 16,667 | $25.74 |
| Jun 30, 2026 | Amy Simon | Sale | 373 | $34.73 |
| Jun 30, 2026 | John M. Evans | Sale | 23,100 | $34.26 |
| Jun 30, 2026 | John M. Evans | Sale | 1,900 | $34.84 |
| Jun 29, 2026 | John M. Evans | Sale | 11,579 | $35.91 |
| Jun 29, 2026 | John M. Evans | Sale | 13,421 | $35.13 |
| Jun 26, 2026 | Llc Fmr | Sale | 251,488 | $35.26 |
| Jun 25, 2026 | Llc Fmr | Sale | 33,372 | $35.12 |
| Apr 1, 2026 | Amy Simon | Sale | 6,700 | $24.58 |
| Apr 1, 2026 | Giuseppe Ciaramella | Sale | 11,810 | $24.58 |
| Apr 1, 2026 | Christine Bellon | Sale | 5,956 | $24.58 |
| Apr 1, 2026 | Bethany J Cavanagh | Sale | 3,242 | $24.58 |
| Apr 1, 2026 | John M. Evans | Sale | 30,078 | $24.58 |
| Mar 31, 2026 | John M. Evans | Sale | 25,000 | $22.76 |
| Mar 30, 2026 | John M. Evans | Sale | 25,000 | $22.37 |
BEAM financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $139.74M | $-79.99M | -0.81 | $-345.10M |
| Dec 31, 2024 | $63.52M | $-376.74M | -4.58 | $-347.25M |
| Dec 31, 2023 | $377.71M | $-132.53M | -1.72 | $-149.19M |
| Dec 31, 2022 | $60.92M | $-289.09M | -4.13 | $22.53M |
| Dec 31, 2021 | $51.84M | $-370.64M | -5.77 | $-66.27M |
Latest balance sheet: total assets $1.39B, total liabilities $318.91M, cash $219.82M (as of Jun 30, 2026).
BEAM earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 4, 2026 | 8-K Item 2.02 (results) | $28.35 |
| May 7, 2026 | 8-K Item 2.02 (results) | $31.47 |
| Feb 24, 2026 | 8-K Item 2.02 (results) | $32.29 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $33.69 |
| Nov 4, 2025 | 8-K Item 2.02 (results) | $22.74 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $18.70 |
| May 6, 2025 | 8-K Item 2.02 (results) | $15.99 |
| Feb 25, 2025 | 8-K Item 2.02 (results) | $29.84 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $25.54 |
| Nov 5, 2024 | 8-K Item 2.02 (results) | $23.93 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on BEAM
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.